Only HAVCR2 significantly upregulated in both GBM and LGG tumors (Figure 1), and its overexpression led to poor survival in all WHO grade, WHO grade II, WHO grade III, and WHO grade IV. This evidence concerns the gene HAVCR2 and glioblastoma.